BiomX

Company Overview

Snapshot

Founded in May 2015 by Eran Elinav, Rotem Sorek, and Tim Lu, BiomX operates with 51–200 employees. The company has raised a total of $146.5M across 11 funding rounds from 15 investors. In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, expanding its presence in security and defense markets.

Business overview

BiomX is a clinical-stage microbiome company focused on developing natural and engineered phage cocktails to target and destroy bacteria implicated in chronic diseases such as cystic fibrosis, atopic dermatitis, inflammatory bowel disease, primary sclerosing cholangitis, and colorectal cancer. The company leverages computational and synthetic biology platforms, drawing on research from the Weizmann Institute of Science and the Massachusetts Institute of Technology. BiomX also aims to expand into security and defense markets through its X Security & Defense division, identifying and commercializing technologies for national security, emergency response, and critical infrastructure protection. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In April 2026, BiomX significantly expanded its strategic focus by acquiring Zorronet, an autonomous AI command-and-control platform, and Dr. Frucht Systems. This move signals a deliberate diversification beyond its core microbiome therapies into the defense and security sectors, leveraging AI for real-time command and control. For investors, this indicates a potential new growth vector and a strategic pivot towards broader technology applications, aiming to address evolving operational needs in national security and critical infrastructure protection.

Company Intelligence Q&A

What was a significant strategic acquisition made by BiomX in 2026?

In April 2026, BiomX acquired Zorronet, an autonomous AI command-and-control platform, to expand its presence in security and defense markets.

What was the outcome of the Phase 1b/2a trial for BX004 in November 2023?

In November 2023, BiomX announced positive topline results from Part 2 of the Phase 1b/2a trial evaluating BX004 for the treatment of chronic pulmonary infections in patients with Cystic Fibrosis.

What was a key development regarding BX004's regulatory pathway in October 2025?

In October 2025, BiomX provided a program update and announced new FDA feedback that could potentially expand the development pathways for BX004.

What was the purpose of the collaboration between BiomX and Boehringer Ingelheim in September 2020?

In September 2020, BiomX entered a collaboration with Boehringer Ingelheim with the goal of discovering microbiome-based biomarkers for Inflammatory Bowel Disease.

What was a notable board appointment for BiomX in November 2019?

In November 2019, BiomX appointed Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as a Board Director.